United States – Pfizer (PFE. N) on Monday said that its respiratory syncytial virus (RSV) vaccine Abrysvo demonstrated robust immune response in the final trial of four groups of adults aged 18 and above with weakened immune systems.
Strong Antibody Response Across All Participants
Pfizer said that even just a single dose of 120 micrograms of the vaccine-elicited neutralizing antibodies against both RSV-A and RSV-B in all participants in the trial, as reported by Reuters.
Abrysvo was well tolerated in the study, and the safety results are similar to other studies of this vaccine, it pointed out.
The drugmaker intends to make the data available to regulatory bodies for consideration.
Target Groups Include Vulnerable Populations
The research took into account two doses of Abrysvo in 203 adults in four groups, namely, lung cancer, end-stage kidney disease, autoimmune inflammatory disorders, and solid organ transplant recipients who are vulnerable to severe RSV-associated disease due to low immunity.
Next Steps for Regulatory Approval
Pfizer vaccine is presently authorized for people aged 60 and over and under the emergency use authorization for women who are between mid of their third trimester of pregnancy to help safeguard the baby.
RSV presents with flu like and cold like signs and symptoms and it is a leading cause of pneumonia in children aged below five years and the elderly, and this results to 177,000 hospitalization and 14,000 deaths in the United States each year.